Precision Assessment of Platelet Rich Plasma for Joint Preservation
| Status: | Recruiting |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA) |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 30 - 70 |
| Updated: | 2/22/2019 |
| Start Date: | April 2, 2018 |
| End Date: | March 29, 2024 |
| Contact: | Jennifer Erhart-Hledik, PhD |
| Email: | jerhart@stanford.edu |
| Phone: | (650) 493-5000 |
Knee Osteoarthritis (OA) is a leading cause of premature disability in Veterans who develop
knee OA at higher rates and younger ages than the population in general. For those with
symptomatic early knee OA, who are years to decades away from meeting clinical indications
for knee replacement surgery, knee injections have been a key treatment option. In recent
years, platelet rich plasma (PRP) injections have gained increasing attention for improving
pain and function in patients with knee OA. Basic science studies also suggest that PRP may
also potentially stimulate repair responses to articular cartilage. However, the mechanisms
of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used,
the PRP composition differs between patients. It is also unknown whether these differences in
PRP composition affect clinical outcomes. This study will address these gaps and provide
critical new and objective information on PRP treatment effects in Veterans and additional
women with early knee OA important to improving clinical use of this new treatment.
knee OA at higher rates and younger ages than the population in general. For those with
symptomatic early knee OA, who are years to decades away from meeting clinical indications
for knee replacement surgery, knee injections have been a key treatment option. In recent
years, platelet rich plasma (PRP) injections have gained increasing attention for improving
pain and function in patients with knee OA. Basic science studies also suggest that PRP may
also potentially stimulate repair responses to articular cartilage. However, the mechanisms
of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used,
the PRP composition differs between patients. It is also unknown whether these differences in
PRP composition affect clinical outcomes. This study will address these gaps and provide
critical new and objective information on PRP treatment effects in Veterans and additional
women with early knee OA important to improving clinical use of this new treatment.
Because very little is known about either the mechanisms of action or objective clinical
outcomes of PRP treatment for knee OA, the investigators propose a prospective "pre-post"
study that will permit us to identify areas where more rigorous clinical outcomes and
mechanistic research may be warranted. The proposed work includes special elements of: (1)
quantitative metrics to assess clinical outcomes, (2) correlation of candidate beneficial
proteins with clinical outcomes, and (3) proteomic evaluation of the injected PRP. This work
will use an innovative multi-disciplinary, personalized approach to evaluate the effects of
PRP composition on both function, as assessed by patient-reported outcomes and gait analysis,
and cartilage matrix structure as assessed by quantitative MRI
outcomes of PRP treatment for knee OA, the investigators propose a prospective "pre-post"
study that will permit us to identify areas where more rigorous clinical outcomes and
mechanistic research may be warranted. The proposed work includes special elements of: (1)
quantitative metrics to assess clinical outcomes, (2) correlation of candidate beneficial
proteins with clinical outcomes, and (3) proteomic evaluation of the injected PRP. This work
will use an innovative multi-disciplinary, personalized approach to evaluate the effects of
PRP composition on both function, as assessed by patient-reported outcomes and gait analysis,
and cartilage matrix structure as assessed by quantitative MRI
Inclusion Criteria:
- symptomatic early knee OA
- full weight-bearing status
- have elected to receive PRP treatment
Exclusion Criteria:
- inflammatory arthritis, gout or recurrent pseudogout
- symptomatic OA of other lower extremity joints
- BMI >35 kg/m2
- use of walking, orthopedic, or prosthetic assistive device
- severe systemic disease defined as American Society of Anesthesiologists (ASA) 3 or
above56
- inability to have MRI
- pregnant or intending to become pregnant during the study
- predominantly patellofemoral disease
We found this trial at
1
site
Palo Alto, California 94304
Principal Investigator: Constance R. Chu, MD
Phone: 650-493-5000
Click here to add this to my saved trials
